** U.S.-listed shares of China-based drug developer Zai Lab
rise 10.6% to $32 premarket
** Co reports data from early-stage study testing its experimental drug to treat previously treated patients with a type of lung cancer
** Says its drug, ZL-1310, helped either remove all signs of cancer from the body or significantly reduce the size of tumor in 74% of patients with recurrent extensive-stage small cell lung cancer
** ZL-1310 belongs to a class of drugs called antibody-drug conjugates, which are targeted cancer therapies that function like "guided missiles" against tumor cells while sparing healthy ones
** Stock up ~6% so far this year as of last close
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.